HUTCHMED Announces Presentation of New Clinical Data on Savolitinib at 2025 World Conference on Lung Cancer

Reuters

Sep 05

HUTCHMED Announces Presentation of New Clinical Data on Savolitinib at 2025 World Conference on Lung Cancer

HUTCHMED (China) Limited has announced that new and updated data from several studies of its compounds will be presented at upcoming international conferences. The data, focusing on the treatment of non-small cell lung cancer (NSCLC), will be showcased at the 2025 World Conference on Lung Cancer in Barcelona, Spain, and the Chinese Society of Clinical Oncology Annual Meeting 2025 in Jinan, China. Among the studies to be presented are updated analyses from the SACHI, SAVANNAH, and a Phase IIIb confirmatory study involving the MET tyrosine kinase inhibitor, savolitinib. This drug is being jointly developed and commercialized by AstraZeneca and HUTCHMED.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2565581111"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565581111\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565581111?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 08:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565581111","market":"nz","top_or_hot":-1,"title":"HUTCHMED Announces Presentation of New Clinical Data on Savolitinib at 2025 World Conference on Lung Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED Announces Presentation of New Clinical Data on Savolitinib at 2025 World Conference on Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HUTCHMED (China) Limited has announced that new and updated data from several studies of its compounds will be presented at upcoming international conferences. The data, focusing on the treatment of non-small cell lung cancer (NSCLC), will be showcased at the 2025 World Conference on Lung Cancer in Barcelona, Spain, and the Chinese Society of Clinical Oncology Annual Meeting 2025 in Jinan, China. Among the studies to be presented are updated analyses from the SACHI, SAVANNAH, and a Phase IIIb confirmatory study involving the MET tyrosine kinase inhibitor, savolitinib. This drug is being jointly developed and commercialized by AstraZeneca and HUTCHMED.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED Announces Presentation of New Clinical Data on Savolitinib at 2025 World Conference on Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED Announces Presentation of New Clinical Data on Savolitinib at 2025 World Conference on Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-05 08:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED Announces Presentation of New Clinical Data on Savolitinib at 2025 World Conference on Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HUTCHMED (China) Limited has announced that new and updated data from several studies of its compounds will be presented at upcoming international conferences. The data, focusing on the treatment of non-small cell lung cancer (NSCLC), will be showcased at the 2025 World Conference on Lung Cancer in Barcelona, Spain, and the Chinese Society of Clinical Oncology Annual Meeting 2025 in Jinan, China. Among the studies to be presented are updated analyses from the SACHI, SAVANNAH, and a Phase IIIb confirmatory study involving the MET tyrosine kinase inhibitor, savolitinib. This drug is being jointly developed and commercialized by AstraZeneca and HUTCHMED.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL1mMvYX:1","article_id":"2565581111","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565581111","pubTimestamp":1757030720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HUTCHMED  Limited has announced that new and updated data from several studies of its compounds will be presented at upcoming international conferences. The data, focusing on the treatment of non-small cell lung cancer , will be showcased at the 2025 World Conference on Lung Cancer in Barcelona, Spain, and the Chinese Society of Clinical Oncology Annual Meeting 2025 in Jinan, China. Among the studies to be presented are updated analyses from the SACHI, SAVANNAH, and a Phase IIIb confirmatory study involving the MET tyrosine kinase inhibitor, savolitinib. This drug is being jointly developed and commercialized by AstraZeneca and HUTCHMED.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED  Ltd. published the original content used t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1587":"次新股","LU0949170426.SGD":"Blackrock Global Multi-Asset Income A6 SGD-H","LU1051770623.HKD":"BGF EUROPEAN EQUITY INCOME \"A6\" (HKDHDG) INC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","AZN.UK":"阿斯利康制药","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0784385170.HKD":"BGF GLOBAL MULTI ASSET INCOME \"A6\" (HKDHGD) INC","LU0575583348.USD":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0784384876.USD":"Blackrock Global Multi-Asset Income A6 USD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0972486137.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AUH\" (USDHDG) ACC","LU0784385840.USD":"Blackrock Global Multi-Asset Income A2 USD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2091194634.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USD) ACC","BK5011":"制药","LU0058720904.USD":"联博国际健康护理基金A","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0640478417.SGD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AGH\" (SGDHDG) ACC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU1153584641.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USDHDG) ACC","LU1880407215.USD":"AMUNDI FUNDS NET ZERO AMBITION TOP EUROPEAN PLAYERS \"A2\" (USD) INC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0526926950.USD":"贝莱德欧洲基金","BK1191":"制药","LU1301847155.USD":"BGF GLOBAL MULTI-ASSET INCOME FUND \"A4G\" (USD) INC","BK1588":"回港中概股","LU1015430645.USD":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU0171293334.USD":"贝莱德英国基金A2","LU1078025761.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USDHDG) ACC","03165":"华夏欧优股对冲","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","00013":"和黄医药"},"translate_title":"和黄医药宣布在2025年世界肺癌大会上展示沃利替尼的新临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":0.9,"03165":0.6,"AZN.UK":0.9},"content_text":"HUTCHMED Announces Presentation of New Clinical Data on Savolitinib at 2025 World Conference on Lung Cancer\n    \n\n        HUTCHMED (China) Limited has announced that new and updated data from several studies of its compounds will be presented at upcoming international conferences. The data, focusing on the treatment of non-small cell lung cancer (NSCLC), will be showcased at the 2025 World Conference on Lung Cancer in Barcelona, Spain, and the Chinese Society of Clinical Oncology Annual Meeting 2025 in Jinan, China. Among the studies to be presented are updated analyses from the SACHI, SAVANNAH, and a Phase IIIb confirmatory study involving the MET tyrosine kinase inhibitor, savolitinib. This drug is being jointly developed and commercialized by AstraZeneca and HUTCHMED.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}